Conjupri® (levamlodipine) – New drug approval

- On December 20, 2019, CSPC Pharmaceutical Group announced the FDA approval of Conjupri (levamlodipine), for the treatment of hypertension in adults and pediatric patients 6 years and older, to lower blood pressure.

- Levamlodipine is the pharmacologically active isomer of amlodipine, a long-acting calcium channel blocker.

- Warnings and precautions for Conjupri include hypotension, increased angina or myocardial infarction, and patients with hepatic failure.

- The most common adverse reaction with amlodipine use is edema which occurs in a dose related manner. Other adverse experiences not dose related (> 1.0%) with amlodipine use are fatigue, nausea, abdominal pain, and somnolence.

- The recommended initial antihypertensive dose of Conjupri in adult patients is 2.5 mg orally once daily, and the maximum dose is 5 mg once daily.

    — The effective antihypertensive oral dose in pediatric patients ages 6 to 17 years is 1.25 mg to 2.5 mg once daily. Doses in excess of 2.5 mg daily have not been studied in pediatric patients.

- CSPC Pharmaceutical Group's launch plans for Conjupri are pending. Conjupri will be available as 1.25 mg, 2.5 mg, and 5 mg tablets.